Neglected Disease(s)   Technologies Available for Licensing from NIH/FDA Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection This invention relates to the use of several peptides from the salivary glands of various sand fly species for the control of leishmania infection. Many of these peptides were shown to be effective in eliciting potent immune responses in animal models and are excellent candidates for the development of vaccines against the disease. A vaccine comprising one of the peptides was used to protect mice challenged with parasites and salivary gland homogenates. A DNA vaccine containing the cDNA for this... More... Technologies Available for Licensing from Non-Profit Institutions Leishmaniasis Harvard University New Delivery Device For Protein Therapeutics And Vaccines The Johns Hopkins University New Uses For Camptothecin Analogs Ref# C09727 Protozoan Infections Overview African Trypanosomiasis Chagas disease Leishmaniasis Malaria

Note that this site uses cookies, Click here for more information.